Design Therapeutics ( DSGN ) Upgraded to Buy: Here's Why
Design Therapeutics (DSGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 31.33% Upside in Design Therapeutics ( DSGN ) : Can the Stock Really Move This High?
The consensus price target hints at a 31.3% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Initiated Phase 1 Single Ascending Dose Trial of DT-216P2 in Healthy Volunteers. Friedreich Ataxia ( FA ) Patient Dosing to Begin in ...
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Aptose Biosciences ( NASDAQ:APTO ) , Aditxt ( NASDAQ:ADTX )
Shares of Global Blue Group Holding AG GB rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 for $7.50 per share. Global Blue Group shares jumped 18.3% to $7.37 in the pre-market trading session.
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Aptose Biosciences ( NASDAQ:APTO ) , Aditxt ( NASDAQ:ADTX )
Shares of GCL Global Holdings Ltd GCL rose sharply in today's pre-market trading. GCL and RF Acquisition Corp. disclosed the successful completion of their business combination. GCL Global shares jumped 107.1% to $6.13 in the pre-market trading session. Here are some other stocks moving in ...
Sangamo Therapeutics, Dave And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Dave ( NASDAQ:DAVE ) , ARKO ( NASDAQ:ARKO )
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Tuesday. Shares of Sangamo Therapeutics, Inc. SGMO fell sharply in today's pre-market trading as the company announced its collaboration and license agreement with Pfizer on giroctocogene ...
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Alset ( NASDAQ:AEI ) , Ambow Education Holding ( AMEX:AMBO )
Shares of Cemtrex, Inc. CETX rose sharply in today's pre-market trading after the company posted stronger-than-expected sales for the fourth quarter, reporting quarterly sales of $18.10 million which beat the analyst consensus estimate of $16.39 million.
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Cullinan Therapeutics ( NASDAQ:CGEM )
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday. Shares of MicroStrategy Incorporated MSTR fell sharply in today's pre-market trading following the company's announcement to issue more shares to finance additional Bitcoin BTC/USD acquisitions.
Lamb Weston Posts Weak Q2 Results, Joins Micron, Lennar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Akso Health ( NASDAQ:AHG ) , Abacus Life ( NASDAQ:ABL )
U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Thursday. Shares of Lamb Weston Holdings, Inc. LW fell sharply in today's pre-market trading as the company posted downbeat quarterly results and lowered FY25 outlook.
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Aethlon Medical ( NASDAQ:AEMD ) , Abacus Life ( NASDAQ:ABL )
Shares of Sangamo Therapeutics, Inc. SGMO rose sharply in today's pre-market trading. Astellas and Sangamo Therapeutics disclosed Capsid license agreement to deliver genomic medicines for neurological diseases. Sangamo Therapeutics shares jumped 19.5% to $2.81 in the pre-market trading session.
NVIDIA Opens BioNeMo to Scale Digital Biology for Global Biopharma and Scientific Industry - NVIDIA ( NASDAQ:NVDA )
ATLANTA, Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- SC24 -- NVIDIA today announced that global pharmaceutical and techbio industry leaders, academic pioneers and AI researchers are adopting the open-source NVIDIA® BioNeMo™ Framework to advance drug discovery and accelerate molecule design.
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - Design Therapeutics ( NASDAQ:DSGN )
CARLSBAD, Calif., Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. DSGN, a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences:
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. ( Nasdaq: DSGN ) , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor ...
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference - Design Therapeutics ( NASDAQ:DSGN )
CARLSBAD, Calif., Sept. 10, 2024 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. DSGN, a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on ...
Palatin Technologies: Utilizing The Melanocortin System As The Basis For Innovation In Drug Development - Targeting Inflammatory & Autoimmune Conditions, Obesity And Sexual Dysfunctions - Palatin Techs ( AMEX:PTN )
Palatin Technologies PTN, a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, received the first FDA approval for a melanocortin agent, for the treatment of hypoactive sexual desire disorder ( HSDD ) ...
Wall Street Analysts Think Design Therapeutics ( DSGN ) Could Surge 39.72%: Read This Before Placing a Bet
The consensus price target hints at a 39.7% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
Friedreich Ataxia ( FA ) and Fuchs Endothelial Corneal Dystrophy ( FECD ) Programs on Track and Advancing Toward Clinical Trials ...
Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying - FTC Solar ( NASDAQ:FTCI ) , Design Therapeutics ( NASDAQ:DSGN )
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update - Design Therapeutics ( NASDAQ:DSGN )
CARLSBAD, Calif., March 12, 2024 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. DSGN, a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m.
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
CARLSBAD, Calif., March 12, 2024 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. ( Nasdaq: DSGN ) , a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, ...
Design Therapeutics, Inc. ( DSGN ) Upgraded to Buy: Here's What You Should Know
Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
NEW YORK, Oct. 11, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ( "Design" or the "Company" ) DSGN. Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc ... PR ...
Nested Therapeutics to Present Preclinical Data for Novel, Potential Best-in-Class Inhibitor of the RAS/MAPK Pathway at 2023 AACR-NCI-EORTC Conference
Nested Therapeutics to Present Preclinical Data for Novel, Potential Best-in-Class Inhibitor of the RAS/MAPK Pathway ... PR ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc ... PR ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
NEW YORK, Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ( "Design" or the "Company" ) DSGN. Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Design Therapeutics, Inc. - DSGN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Design Therapeutics, Inc. ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
NEW YORK, Sept. 17, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ( "Design" or the "Company" ) DSGN. Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Director At This Health Care Company Buys $14.00M of Stock - Design Therapeutics ( NASDAQ:DSGN )
Arsani William, Director at Design Therapeutics DSGN, reported a large insider buy on September 6, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that William purchased 700,000 shares of Design Therapeutics.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
NEW YORK, Sept. 01, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Design Therapeutics, Inc. ( "Design" or the "Company" ) DSGN. Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Over $5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying - ClearOne ( NASDAQ:CLRO ) , Carmell Therapeutics ( NASDAQ:CTCX )
The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc ... PR ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc. - DSGN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Design Therapeutics, Inc ... PR ...
Design Therapeutics' Modified DT-216 May Have Potential, But Analyst Awaits Further Developments - Design Therapeutics ( NASDAQ:DSGN )
RBC Capital Market downgraded Design Therapeutics Inc DSGN from Outperform to Sector Perform with a price target of $7, down from $23. The company reported initial results from the company's Phase 1 multiple-ascending dose clinical trial of DT-216 in patients with Friedrich ataxia.
Nasdaq Falls 100 Points; Siyata Mobile Shares Spike Higher - Design Therapeutics ( NASDAQ:DSGN ) , Delcath Systems ( NASDAQ:DCTH )
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling over 100 points on Tuesday. The Dow traded down 0.82% to 35,017.95 while the NASDAQ fell 0.77% to 13,682.54. The S&P 500, also fell, dropping, 0.87% to 4,450.59. Health care shares fell by just 0.2% on Tuesday.
Why Shares of Design Therapeutics Are Plummeting on Tuesday
The biotech company released phase 1 trial details regarding a Friedreich ataxia therapy.
Crude Oil Down 2%; Home Depot Posts Upbeat Earnings - Design Therapeutics ( NASDAQ:DSGN ) , Delcath Systems ( NASDAQ:DCTH )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 90 points on Tuesday. The Dow traded down 0.75% to 35,042.16 while the NASDAQ fell 0.66% to 13,697.15. The S&P 500, also fell, dropping, 0.76% to 4,455.45. Health care shares fell by just 0.1% on Tuesday.
Dow Falls Over 200 Points; US Retail Sales Top Expectations - Design Therapeutics ( NASDAQ:DSGN ) , Delcath Systems ( NASDAQ:DCTH )
U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.67% to 35,069.60 while the NASDAQ fell 0.47% to 13,723.41. The S&P 500, also fell, dropping, 0.61% to 4,462.38.
Why Is Design Therapeutics Stock Moving Lower Today? - Design Therapeutics ( NASDAQ:DSGN )
Design Therapeutics Inc DSGN reported initial results from the company's Phase 1 multiple-ascending dose ( MAD ) clinical trial of DT-216 in patients with Friedrich ataxia ( FA ) .
Why Delcath Systems Shares Are Trading Higher By Around 58%; Here Are 20 Stocks Moving Premarket - Aptevo Therapeutics ( NASDAQ:APVO ) , Altisource Asset Mgmt ( AMEX:AAMC )
Delcath Systems, Inc. DCTH shares surged 57.7% to $4.93 in pre-market trading after the company reported the FDA approval of HEPZATO KIT™ for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma. Sonim Technologies, Inc.
Design Therapeutics, Getty Images, Sea Limited And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Kanzhun ( NASDAQ:BZ ) , Calliditas Therapeutics ( NASDAQ:CALT )
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today's pre-market trading session. Design Therapeutics, Inc.
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated - Biogen ( NASDAQ:BIIB )
Earlier today, Biogen Inc BIIB agreed to acquire Reata Pharmaceuticals Inc RETA for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.
Why American Equity Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - American Equity Inv ( NYSE:AEL ) , Adicet Bio ( NASDAQ:ACET )
Surgalign Holdings, Inc. SRGA shares surged 49.8% to $0.3401 in pre-market trading after dropping around 19% on Monday.
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
CARLSBAD, Calif., May 31, 2023 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. ( Nasdaq: DSGN ) , a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that management will present at the 2023 Jefferies Healthcare Conference on ...
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference - Design Therapeutics ( NASDAQ:DSGN )
CARLSBAD, Calif., May 31, 2023 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc. DSGN, a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported that management will present at the 2023 Jefferies Healthcare Conference on Wednesday, June ...
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023 - Design Therapeutics ( NASDAQ:DSGN )
Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro Company On-track to Submit Investigational New Drug Application for DT-168 in the Second Half of 2023 CARLSBAD, Calif., April 24, 2023 ( GLOBE NEWSWIRE ) -- Design Therapeutics, Inc.
Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
Treatment with DT-168 Eye Drops Reduced Nuclear Foci and Significantly Improved Mis-Splicing In Vitro ...
First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday - Aspen Aerogels ( NYSE:ASPN ) , Blend Labs ( NYSE:BLND )
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today's session. Blend Labs, Inc. BLND dropped 36.5% to $0.9338 after the company reported worse-than-expected Q4 adjusted EPS and sales results. Nexters Inc.
Illumina, Seagen And Other Big Stocks Moving Higher On Monday - Agenus ( NASDAQ:AGEN ) , First Majestic Silver ( NYSE:AG )
U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today's session. Provention Bio, Inc. PRVB shares gained 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
OpenAI's 37-year-old CEO bet $180 million on a little-known biotech startup that's trying to help people live 10 years longer
OpenAI's 37-year-old CEO bet $180 million on a little-known biotech ... - Business Insider Africa ...
